TREVI THERAPEUTICS INC
NASDAQ: TRVI (Trevi Therapeutics, Inc.)
Last update: 5 hours ago14.95
-0.26 (-1.71%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Trevi Therapeutics, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | -1.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.00 |
|
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.75% |
| % Held by Institutions | 79.20% |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| HEFFERNAN MICHAEL THOMAS | - | 15.04 | -39,473 | -593,674 |
| Aggregate Net Quantity | -39,473 | |||
| Aggregate Net Value ($) | -593,674 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 15.04 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| HEFFERNAN MICHAEL THOMAS | Director | 15 Sep 2026 | Automatic sell (-) | 39,473 | 15.04 | 593,674 |
| HEFFERNAN MICHAEL THOMAS | Director | 15 Sep 2026 | Option execute | 39,473 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |